RARE · XBRL financial data

Ultragenyx Pharmaceutical financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (RARE's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	98	127*	109	147	139	165*	139	166	160	207*	136	214
Research and development	157	161*	178	162	170	188*	166	165	216	203*	187	167
Selling, general and administrative	75	77*	78	81	80	82*	88	87	87	88*	88	88
Operating income (loss)	(145)	(122)*	(165)	(116)	(132)	(122)*	(143)	(108)	(171)	(113)*	(169)	(75)
Interest income	6	9*	9	7	11	10*	7	6	6	7*	6	5
Other income (expense)	(1)	2*	(2)	(2)	3	(4)*	1	2	(1)	(1)*	—	1
Income tax expense (benefit)	1	(4)*	0	1	0	(0)*	1	1	1	1*	1	1
Net income (loss)	(160)	(123)*	(171)	(132)	(134)	(133)*	(151)	(115)	(180)	(129)*	(185)	(92)
Earnings per share, basic USD per share	(2.23)	(1.52)*	(2.03)	(1.52)	(1.40)	(1.39)*	(1.57)	(1.17)	(1.81)	(1.29)*	(1.84)	(0.90)
Earnings per share, diluted USD per share	(2.23)	(1.52)*	(2.03)	(1.52)	(1.40)	(1.39)*	(1.57)	(1.17)	(1.81)	(1.29)*	(1.84)	(0.90)
Weighted average shares, basic millions of shares	72	81*	84	87	95	96*	96	98	100	100*	101	102
Weighted average shares, diluted millions of shares	72	81*	84	87	95	96*	96	98	100	100*	101	102

Fiscal quarters (RARE's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	73	214	112	481	151	174	127	176	203	421	175	125
Marketable securities	370	364	300	283	471	436	367	311	223	259	238	167
Marketable securities, non-current	82	200	157	111	203	135	69	51	22	57	121	144
Accounts receivable	79	73	100	106	93	122	99	124	113	158	121	200
Inventory	32	34	36	40	43	45	46	46	52	52	55	59
Prepaid and other current assets	46	48	—	—	—	40	60	61	53	61	68	55
Total current assets	599	732	596	965	800	817	699	720	643	951	657	606
Property and equipment, net	297	291	285	279	272	266	261	256	250	244	239	235
Right-of-use asset	26	24	—	—	—	26	—	—	—	23	—	—
Goodwill	44	44	44	44	44	44	44	44	44	44	44	44
Total assets	1,238	1,491	1,307	1,618	1,538	1,503	1,312	1,306	1,190	1,532	1,296	1,264
Accounts payable	33	42	41	60	36	39	47	34	41	31	42	39
Accrued liabilities	179	196	149	154	185	241	173	181	221	265	194	221
Total current liabilities	254	280	246	273	285	344	292	293	340	384	325	351
Lease liability, non-current	—	31	—	—	—	30	28	25	22	24	—	—
Total liabilities	1,206	1,216	1,167	1,186	1,185	1,241	1,161	1,148	1,174	1,605	1,525	1,548
Accumulated deficit	(3,264)	(3,388)	(3,558)	(3,690)	(3,823)	(3,957)	(4,108)	(4,223)	(4,403)	(4,532)	(4,717)	(4,809)
Total stockholders' equity	32	275	140	432	347	255	144	151	9	(80)	(236)	(291)
Total liabilities and equity	1,238	1,491	1,307	1,618	1,538	1,503	1,312	1,306	1,190	1,532	1,296	1,264
Common shares outstanding (cover page) millions of shares	82	82	83	92	92	93	95	96	96	97	98	99

Fiscal quarters (RARE's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(160)	(123)*	(171)	(132)	(134)	(133)*	(151)	(115)	(180)	(129)*	(185)	(92)
Depreciation and amortization	7*	8*	9	9*	9*	9*	9	9*	9*	9*	8	8*
Net cash from operating activities	(118)*	(84)*	(191)	(77)*	(67)*	(80)*	(166)	(108)*	(91)*	(100)*	(197)	(97)*
Purchases of property and equipment	4*	2*	3	2*	2*	1*	1	2*	1*	1*	1	1*
Net cash from investing activities	64*	(107)*	94	61*	(276)*	103*	120	71*	117*	(72)*	(49)	44*
Net cash from financing activities	25*	331*	(0)	385*	11*	3*	0	84*	0*	394*	—	—
Net change in cash	(29)*	141*	(97)	368*	(330)*	24*	(45)	49*	26*	221*	(247)	(49)*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Ultragenyx Pharmaceutical	125	214	(97)*	98.6M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Avidity Biosciences	383	0.9*	(170)*	155.1M	2.3 quarters	Q4 FY25 10-KDec 31, 2025
PERRIGO	400	1,023	83*	138.8M	—	Q2 FY26 10-QJun 27, 2026
Vaxcyte	183	not reported	(232)*	148.8M	6.4 quarters	Q2 FY26 10-QJun 30, 2026
Rhythm Pharmaceuticals	40	92	(3.1)*	69.3M	16.9 quarters	Q3 FY26 10-QSep 30, 2026
Viking Therapeutics	678	0	(138)*	127.5M	7.6 quarters	Q3 FY26 10-QSep 30, 2026
Prestige Consumer Healthcare	89	266	71	47.4M	—	Q1 FY27 10-QJun 30, 2026
Protagonist Therapeutics	420	213	219*	64.7M	—	Q2 FY26 10-QJun 30, 2026
Soleno Therapeutics	133	not reported	26	52.1M	—	Q1 FY26 10-QMar 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.